AR034995A1 - Capsula elastica blanda y metodo para su preparacion - Google Patents
Capsula elastica blanda y metodo para su preparacionInfo
- Publication number
- AR034995A1 AR034995A1 ARP020101897A ARP020101897A AR034995A1 AR 034995 A1 AR034995 A1 AR 034995A1 AR P020101897 A ARP020101897 A AR P020101897A AR P020101897 A ARP020101897 A AR P020101897A AR 034995 A1 AR034995 A1 AR 034995A1
- Authority
- AR
- Argentina
- Prior art keywords
- coating
- alcohol
- agent
- soft elastic
- initial state
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 5
- 239000011248 coating agent Substances 0.000 abstract 5
- 238000000576 coating method Methods 0.000 abstract 5
- 239000008177 pharmaceutical agent Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000008199 coating composition Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cápsula elástica blanda que comprende un relleno y un revestimiento, donde dicho relleno comprende: un agente o combinación de agentes farmacéuticos, un alcohol, un ácido graso, y dicho revestimiento comprende: gelatina, y por lo menos un agente plastificante, donde el antedicho revestimiento tiene un estado inicial y un estado de equilibrio, y en dicho estado inicial se subplastifica el revestimiento y el antedicho relleno contiene una cantidad en exceso de alcohol respecto de la cantidad necesaria para solubilizar el agente farmacéutico y dicho alcohol no está presente en el estado inicial de la composición de revestimiento, y donde en el estado de equilibrio se plastifica el revestimiento mediante el alcohol proveniente del relleno para proporcionar una dureza de la cápsula apropiada y el relleno retiene suficiente alcohol como para mantener al agente farmacéutico en solución. Método para preparar dichas cápsulas. Estas cápsulas elásticas blandas pueden ser utilizadas con un amplio rango de agentes farmacéuticos que incluyen antibioticos, agentes farmacéuticos anti-SIDA, como por ejemplo los compuestos inhibidores de la proteasa de VIH, y toda una serie de otros agentes medicinalmente activos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86628501A | 2001-05-25 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034995A1 true AR034995A1 (es) | 2004-04-14 |
Family
ID=25347294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101897A AR034995A1 (es) | 2001-05-25 | 2002-05-22 | Capsula elastica blanda y metodo para su preparacion |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1395249A1 (es) |
| JP (1) | JP2005508294A (es) |
| AR (1) | AR034995A1 (es) |
| CA (1) | CA2448438A1 (es) |
| MX (1) | MXPA03010771A (es) |
| PE (1) | PE20030098A1 (es) |
| UY (1) | UY27306A1 (es) |
| WO (1) | WO2002096395A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| KR20150021510A (ko) | 2012-05-03 | 2015-03-02 | 시플라 리미티드 | 항레트로바이러스 조성물 |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| GB201917252D0 (en) | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| MY121765A (en) * | 1998-07-20 | 2006-02-28 | Abbott Lab | Polymorph of ritonavir |
| SK286305B6 (en) * | 1999-06-04 | 2008-07-07 | Abbott Laboratoires | Improved pharmaceutical formulations comprising ritonavir |
| US6608198B2 (en) * | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
-
2002
- 2002-05-21 JP JP2002592907A patent/JP2005508294A/ja active Pending
- 2002-05-21 EP EP02737019A patent/EP1395249A1/en not_active Withdrawn
- 2002-05-21 WO PCT/US2002/015955 patent/WO2002096395A1/en not_active Ceased
- 2002-05-21 MX MXPA03010771A patent/MXPA03010771A/es not_active Application Discontinuation
- 2002-05-21 CA CA002448438A patent/CA2448438A1/en not_active Abandoned
- 2002-05-22 AR ARP020101897A patent/AR034995A1/es not_active Application Discontinuation
- 2002-05-24 PE PE2002000436A patent/PE20030098A1/es not_active Application Discontinuation
- 2002-05-24 UY UY27306A patent/UY27306A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030098A1 (es) | 2003-02-12 |
| UY27306A1 (es) | 2002-12-31 |
| EP1395249A1 (en) | 2004-03-10 |
| CA2448438A1 (en) | 2002-12-05 |
| MXPA03010771A (es) | 2004-07-01 |
| WO2002096395A1 (en) | 2002-12-05 |
| JP2005508294A (ja) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2191862T3 (es) | Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18. | |
| ES2107235T3 (es) | Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina. | |
| AR024228A1 (es) | Una composicion farmaceutica que comprende un sensibilizador de insulina y otro agente antidiabetico | |
| AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
| AR047799A1 (es) | Capsula de gelatina blanda que contiene una formulacion farmaceutica con al menos un acido graso poli-insaturado omega-3 | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| MX9202328A (es) | Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo. | |
| ES2112547T3 (es) | Composiciones de envuelta de capsulas de gelatina blanda. | |
| BR0309004A (pt) | Matriz para liberação gradual, invariante e independente dos compostos ativos | |
| BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
| BRPI0412059A (pt) | método para a preparação de formulação de liberação controlada | |
| BRPI0406905A (pt) | Espuma de fosfato de clindamicina | |
| KR880701544A (ko) | 이온화 가능한 의약 제제용 용해 시스템 | |
| UY25055A1 (es) | Formulaciones farmacéuticas que contienen voriconazol | |
| BR0015605A (pt) | Composição e uso | |
| ES2109493T3 (es) | Forma galenica para administracion ocular y procedimiento de preparacion. | |
| AR031547A1 (es) | Forma fisica de la sustancia 5-cloro-n-[2-[4-[[[(ciclohexilamino)-carbonil]amino]sulfonil]fenil]etil]-2-metoxibenzamida (gliburida), el uso de dicha sustancia en una tableta o capsula, las tabletas o capsulas que la contienen y las tabletas o capsulas que la contienen asociada con un farmaco para el | |
| ES2176785T3 (es) | Procedimiento de fabricacion de una composicion farmaceutica con liberacion modificada de principio activo, que comprende una matriz. | |
| UY28586A1 (es) | Formas de administración masticables, no comprimidas dosificadas individualmente | |
| AR034995A1 (es) | Capsula elastica blanda y metodo para su preparacion | |
| CO2023008949A2 (es) | Forma cristalina de tolebrutinib, método de preparación y uso de la misma | |
| AR021921A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido. | |
| BRPI0418070A (pt) | composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais | |
| ES2062697T3 (es) | Procedimiento para la incorporacion en pellets de principios activos protegidos contra la degradacion en la panza de los rumiantes. | |
| CL2004001843A1 (es) | Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |